This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biotech Acquisition to Dissolve, Liquidate MT
Biotech Acquisition Company(NasdaqCM:BIOT) dropped from NASDAQ Composite Index CI
Biotech Acquisition Says New Sponsor to Make Additional Contributions Related to Proposed Business Combination Extension MT
Biotech Acquisition Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Biotech Acquisition Company announced that it expects to receive $0.25 million in funding CI
Biotech Acquisition, Blade Therapeutics Agree to Terminate Merger Agreement MT
Biotech Acquisition Company cancelled the transaction announced on November 8, 2021 CI
Blade Therapeutics, Inc. cancelled the acquisition of Biotech Acquisition Company from Biotech Sponsor LLC and others in a reverse merger transaction. CI
Biotech Acquisition Postpones Extraordinary Meeting of Shareholders to Approve Proposed Merger With Blade Therapeutics MT
Biotech Acquisition Company Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Blade Therapeutics Gets FDA Feedback Letter for Cudetaxestat DJ
Biotech Acquisition Company Auditor Raises 'Going Concern' Doubt CI
Blade Therapeutics Says Treatment for Lung Scarring Condition Was Well Tolerated in Phase 1 Study MT
Blank Check Firm Biotech Acquisition to Merge With Blade Therapeutics MT
Biotech Acquisition Company announced that it expects to receive $24.3 million in funding from Bristol-Myers Squibb Company, Deerfield Management Company, L.P., Pfizer Venture Investments LLC, Osage University Partners, MPM Asset Management, L.L.C. and other investors CI
Blade Therapeutics, Inc. entered into a definitive Agreement and Plan of Merger to acquire Biotech Acquisition Company from Biotech Sponsor LLC and others in a reverse merger transaction. CI
Certain Class B Ordinary Shares of Biotech Acquisition Company are subject to a Lock-Up Agreement Ending on 25-JUL-2021. CI
Biotech Acquisition Company(NasdaqCM:BIOT) added to NASDAQ Composite Index CI
Biotech Acquisition Company Announces Resignation of Michael Tillman as an Advisor CI
Biotech Acquisition Company announced that it has received $6 million in funding from Biotech Sponsor LLC CI
Biotech Acquisition Company has completed an IPO in the amount of $200 million. CI
Biotech Acquisition Company has filed an IPO in the amount of $200 million. CI
Biotech Acquisition Company announced that it expects to receive $6 million in funding from Biotech Sponsor LLC CI
Chart Biotech Acquisition Company
More charts
Biotech Acquisition Company is a blank check company. The Company is created for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. The Company focuses for a target business in the healthcare sector. It has no operations and has no revenues.
More about the company
  1. Stock Market
  2. Equities
  3. BIOT Stock
  4. News Biotech Acquisition Company
  5. Biotech Acquisition Says New Sponsor to Make Additional Contributions Related to Proposed Business Combination Extension